Adelaide Research & Scholarship: Search

Search

Results 1-6 of 6 (Search time: 0.001 seconds).

previous
1
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2013	Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study	Ross, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.
	2010	Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy	Hiwase, D.; White, D.; Zrim, S.; Saunders, V.; Vaz de Melo, J.; Hughes, T.
	2010	Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR	Ross, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Bartley, P.; Slader, C.; Field, C.; Dang, P.; Filshie, R.; Mills, A.; Grigg, A.; Vaz de Melo, J.; Hughes, T.
	2011	Do we have to kill the last CML cell?	Ross, D.; Hughes, T.; Vaz de Melo, J.
	2010	Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors	Hiwase, D.; White, D.; Powell, J.; Saunders, V.; Zrim, S.; Frede, A.; Guthridge, M.; Lopez, A.; D'Andrea, R.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.
	2011	SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia	Esposito, N.; Colavita, I.; Quintarelli, C.; Sica, A.; Peluso, A.; Luciano, L.; Picardi, M.; Vecchio, L.; Buonomo, T.; Hughes, T.; White, D.; Radich, J.; Russo, D.; Branford, S.; Saglio, G.; Vaz de Melo, J.; Martinelli, R.; Ruoppolo, M.; Kalebic, T.; Martinelli, G.; et al.